UBS raised the firm’s price target on MetLife (MET) to $102 from $98 and keeps a Buy rating on the shares. The firm adjusted targets in the North American life insurance group as part of a Q1 earnings preview. UBS expects continued focus on disability margins with “relatively limited wiggle-room” given cyclicality and economic uncertainty. The firm rolled its target to 2027 from 2026 estimates.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MET:
- MetLife price target lowered to $89 from $92 at Barclays
- MetLife Issues Preliminary First-Quarter Variable Investment Income
- MetLife re-initiated with an Outperform at Keefe Bruyette
- MetLife price target lowered to $88 from $91 at TD Cowen
- MetLife recommends shareholders reject mini-tender offer by Potemkin